Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-06-14
2011-06-14
Wen, Sharon (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S141100
Reexamination Certificate
active
07959919
ABSTRACT:
The present invention discloses the method of inhibiting complement activation mediated by factor B inhibitors, that involves: (a) inhibiting factor B binding to properdin-bound C3b; (b) inhibiting the release of Bb; (c) inhibiting the activation of neutrophils, monocytes, platelets, and endothelium; or (d) inhibiting/reducing the formation of PC3bBb, C3a, C5a, and MAC.The present invention also discloses the novel use of factor B inhibitors in the treatment of various immunological disorders, resulting either primarily from direct immune responses such as rheumatoid arthritis, anaphylactic shock, myasthenia gravis, asthma, Alzheimer's disease, and the like, or secondarily from clinical conditions such as cardiopulmonary bypass inflammation, vascular stenosis and restenosis, burn injury, and the like.
REFERENCES:
patent: 6333034 (2001-12-01), Gupta-Bansal et al.
patent: WO 00/21559 (2000-04-01), None
Harlow, E et al. Antibodies: A Laboratory Manual. [1988] pp. 72-77, 92-97, 128-135, 141-157 and 628-631.
Owens et al. (Journal of Immunological Methods, 1994, 168:149-165).
Clardy, C.W. Complement Activation by Whole Endotoxin Is Blocked by a Monoclonal Antibody to Factor B.Infection and Immunity, 1994, 62C101, 4599-4555.
Matsumoto, M. et al., Abrogation of the Alternative Complement Pathway by Targeted Deletion of Murine Factor B.Proc. Natl. Acad. Sci. USA. 1997, 94, 8720-8725.
Hourcade, D.E. et al. Analysis of the Short Consensus Repeats of Human Complement Factor B by Site-Directed Mutagenesis.J. Biol. Chem. 1995, 270 (34), 19716-19722.
Hensley P. et. al. The Effects of Metal Ions and Temperature on the Interaction of Cobra Venom Factor and Human Complement Factor B.J. Biol. Chem. 1986, 261 (24), 1103-11044.
Hourcade, D. E. et. al. Mutations of the Type A Domain of Complement Factor B That Promote High-Affinity C36-Binding.The Journal of Immunology, 1999, 162, 2906-2911.
Horiuchi, T. et. al. Human Complement Factor B: cDNA Cloning, Nucleotide Sequencing, Phenotypic Conversion. by Site-Directed Mutagenesis and Expression.Molecular Immunology1993, 30 (17), 1587-1592.
Arnstead et al., “Removal of activated complement from shed blood: comparison of high-and low-dilutional haemofiltration”. Acta Anaesthesiol Scand. Aug. 1998;42(7):811-5, Abstract Only.
Buono et al., “Influence of C3 Deficiency on Athrerosclerosis”. Circulation 2002;105;3025-3031.
Carter et al., “Humanization of an anti-p185HER2antibody for human cancer therapy”, Proc. Natl. Acad, Sci USA, vol. 89, pp. 4285-4289, May 1992.
Chenoweth, D.E., Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med, 1981. 304(9): p. 497-503, Abstract Only.
Clardy, C.W., “Complement activation by whole endotoxin is blocked by a monoclonal antibody to factor B.” Infect Immun, 1994. 62(10): pp. 4549-4555.
Dahl et al., “MASP-3 and its association with distinct complexes of the Mannan-Binding Lectin Complement Activation Pathway”, Immunity, vol. 15, 127-135, Jul. 2001.
Dang, “Relationship between developmental stenosis of cervical spinal canal and spinal cord injury”, Zhonghua Wai Ke Za Zhi, Nov. 1992;29(12):724-6, 796, Abstract Only.
Dreyer, WJ, et al. “Neutrophil accumulation in ischemic canine myocardium. Insights into time course distribution, and mechanism of localization during early reperfusion”. Circulation 1991; 84;400-411.
Eaton S., et al. “Assay for Plasma Complement Activation by x-ray contrast media”. Invest Radiol, 1990. 25(7):p. 789-92, Abstract Only.
Entman, Mark L., et al. “Neutrophil induced oxidative injury of cardiac myocytes”, J. Clin. Invest. vol. 90, 1992, p. 1335-1345.
Espinoza, Diego G. et al., “Macrophage Depletion Diminishes Lesion Size and Severity in Experimental Choroidal Neovascularization”, Invest Ophthalmol Vis Sci. 2003:44:3586-3592.
Frederick, G.N., L. Truedsson, and A.G. Sjoholm, “New procedure for the detection of complement deficiency by ELISA. Analysis of activation pathways and circumvention of rheumatoid factor influence”. J Immunol Methods, 1993: 166(2): p. 263-70, Abstract Only.
Gyoten, M.,Activation of the complement system and cytokine production by radiographic contrast media in vascular endothelial cell in vitro, Nippon Igaki Hoshasen Gakkai Zasshi Dec. 1998;58(14):811-5, Abstract Only.
Halstensen TS, Brandtzaeg P.,Local Complement activation in inflammatory bowel disease, Immunol Res. 1991; 10(3-4): 485-92, Abstract Only.
Horiuchi, T., et al.,Human complement factor B: cDNA cloning, nucleotide sequencing, phenotypic conversion by site-directed mutagenesis and expression. Mol Immunol, 1993. 30(17): p. 1587-92, Abstract Only.
Hourcade, D.E., L.M. Wagner, and T.J. Oglesby,Analysis of the short consensus repeats of human complement factor B by site-directed mutagenesis. J Biol Chem, 1995. 270(34): p. 19716-22.
Ikeda, Ken et al.,Serum lectin with known structure activates complement through the classical pathway, Journal of Biological Chemistry. 1987 262(16): p. 7451-7454.
Isaacs, J.D., et al.,Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J Immunol, 1992. 148(10): p. 3062-71.
Jones HM, et al.,Cardiopulmonary bypass and complement activation. Involvement of classical and alternative pathways., Anaesthesia. Jun. 1982;37(6):629-33, Abstract Only.
Jones, Peter T. et al.,Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature 321, 522-525, May 29, 1986, Abstract Only.
Kawana S. et al.,Membrane attack complex of complement in Henoch-Schönlein purpura skin and nephristis, Arch Dermatol Res. 1990;282(3)187-7, Abstract Only.
Kilpatrick, David C.,Mannan-Binding lectin: clinical significance and applications, Biochimica et Biophysica Acta 1572 (2002) 401-413.
Kitano A., et al.,New treatment of ulcersative colitis with k-76, Dis Colon Rectum. Jun. 1992;35(6):560-7, Abstract Only.
Kolios G. et al.,Mediators of inflammation: production and implication in inflammatory bowel disease. Hepatogastroenterology. Sep.-Oct. 1998;45(23):1601-9, Abstract Only.
Lonberg Nils, et al.,Antigen-specific human antibodies from mice comprising four distinct genetic modifications, Nature 368, 856-859: Apr. 28, 1994, Abstract Only.
Marks, J.D. et al.,By-passing immunization. Human antibodies from v-gene libraries displayed on phage, J Mol Biol. Dec. 5, 1991;222(3)581-597, Abstract Only.
Moore, F.D., Jr., et al.,The effects of complement activation during cardiopulmonary bypass. Attenuation by hypothermia, heparin, and hemodilution. Ann Surg, 1988. 208(1): p. 95-103, Abstract Only.
Morgan BP et al.,Measurement of terminal complement complexes in rheumatoid arthritis, Clin Exp Immunol. Sep. 1998;73(3):473-8, Abstract Only.
Morgan BP, Walport MJ,Complement deficiency and disease, Immunol Today. Sep. 1991;12(9):301-6, Abstract Only.
Morrison SL et al.,Chimeric human molecules: mouse antigen-binding domains with human constant region domains, Proc Natl Acad Sci U S A. Nov. 1984;81(21):6851-5, Abstract Only.
Nakano S, Engel AG,Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients, Neurology. Jun. 1993;43(6):1167-72, Abstract Only.
Niculescu F, Rus H.Complement activation and atherosclerosis, Mol Immunol. Sep.-Oct. 1999;36(13-14):949-55, Abstract Only.
Pack P. et al.,Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli, Biotechnology (NY). Nov. 1993;11(11):1271-7, Abstract Only.
Pangburn, M.K., R.D. Schreiber, and H.J. Muller-Eberhard,Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med, 1981. 154(3): p. 856-67, Abstract Only.
Polhill, R.B., Jr., K.M. Pruitt, and R.B. Johnston, Jr.,Kinetic assess
NovelMed Therapeutics, Inc.
Tarolli, Sundheim Covell & Tummino LLP
Wen Sharon
LandOfFree
Method of inhibiting factor B-mediated complement activation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting factor B-mediated complement activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting factor B-mediated complement activation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2722880